American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Foghorn Therapeutics Inc. (FHTX)

$2.00 -0.50% NASDAQ: FHTX · 15-min delayed

CAMBRIDGE, Massachusetts
Public · NASDAQ: FHTX
106 employees

Visit website Follow

$284.8MMarket cap

$30.9MRevenue · FY2025

-$74.3MNet income

106Employees

FHTXNASDAQ

2020IPO

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: FHTX
Employees: 106
IPO date: Oct 23, 2020
Headquarters: 500 TECHNOLOGY SQUARE
CAMBRIDGE, Massachusetts 02139
Phone: 617-586-3100
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: FHTX Nasdaq
SEC CIK: 1822462
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Foghorn Therapeutics Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/foghorn-therapeutics-inc/"><img src="https://americancompanies.com/badge/foghorn-therapeutics-inc.svg" alt="Foghorn Therapeutics Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Foghorn Therapeutics Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $30.9M
Net income: -$74.3M
Total assets: $198.1M
Market cap: $284.8M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: FHTX

$2.00 -0.50%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.85 $7.07

52-week range

Market cap: $284.8M
Shares outstanding: 142.4M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Oct 23, 2020

Foghorn Therapeutics Inc. (FHTX) Stock Price

Reported a net loss of $74.3M in FY2025.
Trading 72% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Foghorn Therapeutics Inc..

Write a review

Newsroom

News about Foghorn Therapeutics Inc.

Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director GlobeNewswire Inc. · 2026-07-01 · neutral Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting GlobeNewswire Inc. · 2026-04-09 · positive Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff Benzinga · 2026-01-14 · positive Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 GlobeNewswire Inc. · 2026-01-10 · positive 4DMT Appoints Kristian Humer as Chief Financial Officer GlobeNewswire Inc. · 2025-11-17 · neutral Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences GlobeNewswire Inc. · 2025-08-27 · positive

News & sentiment via Polygon.io

FAQ

Foghorn Therapeutics Inc.: frequently asked questions

Is Foghorn Therapeutics Inc. an American company?

Foghorn Therapeutics Inc. is a US-based company headquartered in Cambridge, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Foghorn Therapeutics Inc. headquartered?

Foghorn Therapeutics Inc. is headquartered in Cambridge, Massachusetts, United States.

Is Foghorn Therapeutics Inc. publicly traded?

Yes — Foghorn Therapeutics Inc. is a publicly traded company. Its stock trades under the ticker symbol FHTX on the NASDAQ.

What does Foghorn Therapeutics Inc. do?

Foghorn Therapeutics Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore